This company listing is no longer active
De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
NeuBase Therapeutics Inkomsten in het verleden
Verleden criteriumcontroles 0/6
NeuBase Therapeutics has been growing earnings at an average annual rate of 26.6%, while the Biotechs industry saw earnings growing at 13.5% annually.
Belangrijke informatie
26.6%
Groei van de winst
28.1%
Groei van de winst per aandeel
| Biotechs Groei van de industrie | -14.6% |
| Inkomstengroei | n/a |
| Rendement op eigen vermogen | -170.2% |
| Nettomarge | n/a |
| Laatste winstupdate | 31 Mar 2023 |
Recente prestatie-updates uit het verleden
Geen updates
Recent updates
Opbrengsten en kosten
Hoe NeuBase Therapeutics geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 31 Mar 23 | 0 | -25 | 11 | 13 |
| 31 Dec 22 | 0 | -30 | 12 | 18 |
| 30 Sep 22 | 0 | -34 | 12 | 21 |
| 30 Jun 22 | 0 | -33 | 13 | 20 |
| 31 Mar 22 | 0 | -33 | 13 | 20 |
| 31 Dec 21 | 0 | -29 | 12 | 17 |
| 30 Sep 21 | 0 | -25 | 12 | 14 |
| 30 Jun 21 | 0 | -23 | 11 | 13 |
| 31 Mar 21 | 0 | -18 | 10 | 9 |
| 31 Dec 20 | 0 | -17 | 10 | 8 |
| 30 Sep 20 | 0 | -17 | 10 | 7 |
| 30 Jun 20 | 0 | -33 | 13 | 19 |
| 31 Mar 20 | 0 | -31 | 12 | 18 |
| 31 Dec 19 | 0 | -29 | 11 | 17 |
| 30 Sep 19 | 0 | -26 | 9 | 16 |
Kwaliteitswinsten: O7P is currently unprofitable.
Groeiende winstmarge: O7P is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: Insufficient data to determine if O7P's year-on-year earnings growth rate was positive over the past 5 years.
Versnelling van de groei: Unable to compare O7P's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: O7P is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (3%).
Rendement op eigen vermogen
Hoge ROE: O7P has a negative Return on Equity (-170.17%), as it is currently unprofitable.